The current treatment mainly focuses on blood pressure management using renin–angiotensin system (RAS) inhibitors (angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB)), which may ameliorate proteinuria and decrease the rate of progression to end-stage renal disease. This evidence concerns the gene ACE and stage 5 chronic kidney disease.